HOXA4 Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients

Table 2

Risk association between HOXA4 methylation status and IM response among CML patients.

HOXA4 methylation (%)	CML Patients on IM therapy			𝑃 value	OR (95% CI)
	Good Response	Resistance	Patients; Total
0–49	15	7	22	—	Reference
50–100	23	50	73	0.003*	4.658 (1.673–12.971)

*Chi-Square test, 𝑃<0.05 significant at 95% CI.